Meda strengthens allergy product portfolio in Europe with EpiPen® Auto-Injector

Meda strengthens allergy product portfolio in Europe with EpiPen®
Auto-Injector

Meda has signed a long-term license agreement with the specialty
division of Mylan Inc. (Nasdaq: MYL), Dey Pharma, L.P., for exclusive
marketing and distribution rights of EpiPen® (epinephrine) Auto-Injector
in Europe. EpiPen is used for emergency treatment of severe allergic
reactions (anaphylaxis). Anaphylaxis can occur quickly (often within a
couple of minutes) and may be life-threatening.

EpiPen is a well-established brand and is the market leader in several
European countries as well as other parts of the world, including the
U.S. Beginning in 2011, the distribution rights to EpiPen for Europe
will be transferred to Meda from current distributors. As part of the
agreement with Dey, Meda will pay a combination of up-front and
milestone payments totaling a mid-single million EUR figure. The current
market size for epinephrine auto-injectors in Europe is approximately 40
MEUR.

“EpiPen strengthens our allergy franchise in Europe, and we look forward
to working closely with Dey to ensure that this important and
life-saving product is accessible to those who are at-risk of an
allergic emergency,” said Anders Lönner, CEO Meda AB.

Meda's exclusive rights to the product also include the next generation
EpiPen, featuring more patient-friendly features. The next generation
EpiPen is currently available in many markets outside of Europe,
including the U.S. Meda will be responsible for regulatory filings in
Europe of the next generation EpiPen.

Dey Pharma President Carolyn Myers, Ph.D. commented: “It's been long
known and understood that one of our primary objectives is to expand the
growth and breadth of our EpiPen franchise. After a careful and thorough
analysis, we are extremely pleased to partner
with Meda, a company with a strong and proven expertise in the allergy
category as well as an expansive pan-European marketing platform. This
collaboration strategically positions us to grow the EpiPen franchise
and expand access to this important product in Europe. Many Europeans
are at risk of allergic emergency, some of whom don't even know it.
Along with expanded educational programs, we plan to continue to grow
the EpiPen Auto-Injector franchise in Europe, including the upcoming
launch of our next generation EpiPen product with Meda.”

For questions, please contact:

Meda: Anders Larnholt, Vice President Corporate Development & IR      
ph: +46 709-458 878

Mylan: Mike Laffin, Vice President, Global Public Affairs            
            ph: +1-724-514-1968
 

MEDA AB (publ) is a leading international specialty pharma company.
Meda's products are sold in 120 countries worldwide and the company is
represented by its own organizations in 50 countries. The Meda share is
listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in
Stockholm. Find out more, visit www.meda.se (http://www.meda.se/).

Dey Pharma L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a
specialty pharmaceutical company focused on the development,
manufacturing and marketing of prescription drug products for the
treatment of respiratory diseases, severe allergic reactions and
psychiatric disorders. The company puts patients first and facilitates
efficient, cost-effective partnerships with customers. For more
information, please visit www.dey.com (http://www.dey.com/).